Top Qs
Timeline
Chat
Perspective
Pegfilgrastim
Monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.[20] It serves to stimulate the production of white blood cells (neutrophils).[20][22] Pegfilgrastim was developed by Amgen.[23]
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[24]
Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[25][24]
Pegfilgrastim was approved for medical use in the United States in January 2002, in the European Union in August 2002, and in Australia in September 2002.[23][21][26][27][28] It is on the World Health Organization's List of Essential Medicines.[29]
Remove ads
Medical uses
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).[20][30][31]
Remove ads
Society and culture
Legal status
In January 2025, the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dyrupeg, intended to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy.[5] The applicant for this medicinal product is CuraTeQ Biologics s.r.o.[5] Dyrupeg is a biosimilar medicinal product that is highly similar to the reference product Neulasta, which was authorized in the EU in August 2002.[5] Dyrupeg was authorized for medical use in the European Union in March 2025.[5][32]
In June 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vivlipeg, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia after cytotoxic chemotherapy.[33] The applicant for this medicinal product is Biosimilar Collaborations Ireland Limited.[33] Vivlipeg is a biosimilar medicinal product that is highly similar to Neulasta.[33]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads